| dbo:abstract |
Telesta Therapeutics Inc. was a publicly traded, Canadian pharmaceutical company based in Montreal, Quebec. It was acquired by ProMetic Life Sciences in 2016. CEO Michael Berendt; prior to joining Telesta, was the president and CEO of Aegera Therapeutics. Telesta was listed on the Toronto Stock Exchange under the symbol TST. (en) |
| dbo:fate |
Acquired byProMetic Life Sciences (en) |
| dbo:formerName |
Bioniche Life Sciences Inc. (en) |
| dbo:industry |
dbr:Pharmaceutical_industry |
| dbo:type |
dbr:Public_company |
| dbo:wikiPageID |
45197904 (xsd:integer) |
| dbo:wikiPageLength |
6659 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1117599167 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:ProMetic_Life_Sciences dbr:Quebec dbr:FDA_Fast_Track_Development_Program dbr:Bladder_cancer dbr:Pharmaceutical_company dbr:Valrubicin dbr:Public_company dbr:Orphan_drug dbr:Montreal dbr:Board_of_directors dbr:Pharmaceutical_industry dbr:Toronto_Stock_Exchange dbr:USFDA dbr:Aegera_Therapeutics dbr:Food_and_Drug_Administration dbr:Biologic_license_application dbc:Companies_formerly_listed_on_the_Toronto_Stock_Exchange dbr:Adverse_event dbc:Pharmaceutical_companies_of_Canada dbr:Biologics_license_application dbr:Publicly_traded |
| dbp:fate |
Acquired by ProMetic Life Sciences (en) |
| dbp:formerName |
Bioniche Life Sciences Inc. (en) |
| dbp:industry |
dbr:Pharmaceutical_industry |
| dbp:keyPeople |
Michael Berendt (en) |
| dbp:name |
Telesta Therapeutics Inc. (en) |
| dbp:type |
dbr:Public_company |
| dbp:wikiPageUsesTemplate |
dbt:As_of dbt:End_date dbt:Infobox_company dbt:Reflist dbt:TSX_was |
| dct:subject |
dbc:Companies_formerly_listed_on_the_Toronto_Stock_Exchange dbc:Pharmaceutical_companies_of_Canada |
| rdf:type |
owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation |
| rdfs:comment |
Telesta Therapeutics Inc. was a publicly traded, Canadian pharmaceutical company based in Montreal, Quebec. It was acquired by ProMetic Life Sciences in 2016. CEO Michael Berendt; prior to joining Telesta, was the president and CEO of Aegera Therapeutics. Telesta was listed on the Toronto Stock Exchange under the symbol TST. (en) |
| rdfs:label |
Telesta Therapeutics (en) |
| owl:sameAs |
freebase:Telesta Therapeutics yago-res:Telesta Therapeutics wikidata:Telesta Therapeutics https://global.dbpedia.org/id/u7ot |
| prov:wasDerivedFrom |
wikipedia-en:Telesta_Therapeutics?oldid=1117599167&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:Telesta_Therapeutics |
| foaf:name |
Telesta Therapeutics Inc. (en) |
| is dbo:wikiPageRedirects of |
dbr:Bioniche_Life_Sciences dbr:MCNA dbr:Telesta_Therapeutics_Inc. |
| is dbo:wikiPageWikiLink of |
dbr:BNC dbr:Bioniche_Life_Sciences dbr:Liminal_BioSciences dbr:MCNA dbr:TST dbr:Telesta_Therapeutics_Inc. |
| is foaf:primaryTopic of |
wikipedia-en:Telesta_Therapeutics |